🚀 Incredible milestone for innovation in oncology!
A great way to kick off the year in life sciences. 🤝 It’s fantastic to see Amgen's acquisition of Dark Blue Therapeutics, a cutting-edge biotech spun out of Oxford focused on precision oncology, in a deal valued at up to $840 million.
This deal is more than a headline; it’s a real validation of innovation in precision oncology. Dark Blue’s work shows how deep scientific insight and focus on unmet need can translate into meaningful outcomes for patients and attract strategic investment from global leaders.
Moments like this reinforce why working in the life sciences is so exciting, where collaboration, discovery, and long-term vision can genuinely shape the future of medicine. 🧪🫶
A great start to the year, and I’m looking forward to seeing what else 2026 brings. 😍
Read more here: 👇
https://lnkd.in/e_b3yfwEhttps://lnkd.in/e_b3yfwE
Back
- Publish Date: Posted 25 days ago
- Author: Sarah Seaford